<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03651765</url>
  </required_header>
  <id_info>
    <org_study_id>RM-493-022</org_study_id>
    <nct_id>NCT03651765</nct_id>
  </id_info>
  <brief_title>Long Term Extension Trial of Setmelanotide</brief_title>
  <official_title>Long Term Extension Trial of Setmelanotide (RM-493) for Patients Who Have Completed a Trial of Setmelanotide for the Treatment of Obesity Associated With Genetic Defects Upstream of the MC4 Receptor in the Leptin-melanocortin Pathway</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rhythm Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rhythm Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a long-term extension trial to study the safety and tolerability of continued
      setmelanotide treatment in patients who have completed a previous clinical trial on treatment
      with setmelanotide for obesity associated with genetic defects upstream of the MC4 receptor
      in the leptin-melanocortin pathway.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this protocol is to continue the assessment of setmelanotide treatment in
      patients who have successfully completed all critical study evaluations in a prior trial
      (index protocol) of setmelanotide for the treatment of obesity associated with genetic
      defects in the leptin-melanocortin pathway upstream of the MC4 receptor. The primary
      objectives of this extension trial are to explore the long-term safety and tolerability of
      setmelanotide for up to 5 years or until drug is otherwise available through authorized use.
      Patients can enter this protocol immediately upon completion of their index protocol such
      that dosing of setmelanotide continues without gaps in therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2018</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label treatment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of setmelanotide</measure>
    <time_frame>2 years</time_frame>
    <description>Frequency and severity of adverse events (AEs) as well as changes in physical examinations, electrocardiograms (ECGs), vital signs (including resting BP and HR), laboratory evaluations, and injection site reactions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight Loss</measure>
    <time_frame>2 years</time_frame>
    <description>Maintenance or continued weight loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hunger</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment of hunger using a Hunger Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Fat Mass</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment of body composition as measured by bioelectrical impedance (BIA) or Dual-energy x-ray absorptiometry (DXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment of waist circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in total body mass, non-bone lean mass, and bone density</measure>
    <time_frame>2 years</time_frame>
    <description>Percent change in total body mass, non-bone lean mass, and bone density measured in kg and waist circumference .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid Labs</measure>
    <time_frame>2 years</time_frame>
    <description>Changes in fasting lipids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Quality of Life</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment of quality of life measured by quality of life questionnaires (IWQOL for adults and PEDSQL for pediatrics)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Health Status</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment of health status measured by the SF-36 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker Assays</measure>
    <time_frame>2 years</time_frame>
    <description>Assays to be collected and analyzed: LH, FSH, TSH, free T4, IGF-1, IGFBP-3, Serum procollagen type 1 N-propeptide, COOH-terminal telopeptide of type 1 collagen, N-terminal telopeptide of type 1 collagen, Bone-specific alkaline phosphatase, osteocalcin.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Obesity Associated With Defects in Leptin-melanocortin Pathway</condition>
  <arm_group>
    <arm_group_label>Setmelanotide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Setmelanotide</intervention_name>
    <description>Once daily subcutaneous injection</description>
    <arm_group_label>Setmelanotide</arm_group_label>
    <other_name>RM-493</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Completed participation (all critical study evaluations) on active drug in a previous
             setmelanotide study for obesity associated with genetic defects upstream of the MC4
             receptor in the leptin-melanocortin pathway.

          2. Study participant and/or parent or guardian is able to communicate well with the
             investigator, to understand and comply with the requirements of the study, and be able
             to understand and sign the written informed consent/assent.

          3. Female participants of child-bearing potential must agree to use contraception as
             outlined in the protocol. Female participants of non-childbearing potential, defined
             as surgically sterile (status post hysterectomy, bilateral oophorectomy, or bilateral
             tubal ligation) or post-menopausal for at least 12 months (and confirmed with a FSH
             level in the post-menopausal lab range), do not require contraception during the
             study.

          4. Male participants with female partners of childbearing potential must agree to a
             double barrier method if they become sexually active during the study or the extension
             phase. Male patients must not donate sperm during and for 90 days following their
             participation in the study.

        Exclusion Criteria:

        1. Current, clinically significant disease, if severe enough to interfere with the study
        and/or would confound the results. Any such patients should be discussed with the sponsor
        prior to inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Murray Stewart, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Rhythm Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matt Webster</last_name>
    <phone>8572644105</phone>
    <email>mwebster@rhythmtx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olga Ohayon</last_name>
    <phone>8572644289</phone>
    <email>oohayon@rhythmtx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Honor Health Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Boone</last_name>
      <phone>480-323-4936</phone>
      <email>Steven.Boone@honorhealth.com</email>
    </contact>
    <investigator>
      <last_name>Janes Swain</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Institutes of Health</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheila Brady</last_name>
      <phone>301-451-3783</phone>
      <email>bradys@mail.nih.gov</email>
    </contact>
    <investigator>
      <last_name>Jack Yanovski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Geisinger Health System</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822-2607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Seiler</last_name>
      <phone>570-214-2740</phone>
      <email>jlseiler@geisinger.edu</email>
    </contact>
    <investigator>
      <last_name>Christopher Still, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Health Science Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raquel Mack</last_name>
      <phone>901-287-6869</phone>
      <email>rmack7@uthsc.edu</email>
    </contact>
    <investigator>
      <last_name>Joan Han</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Manci</last_name>
      <phone>715-389-3748</phone>
      <email>mancl.kathleen@mcrf.mfldclin.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Haws</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peel Memorial Hospital</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karlee Trafford</last_name>
      <email>Karlee.Trafford@illingworthresearch.com</email>
    </contact>
    <investigator>
      <last_name>Allison Bahm</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Kühnen</last_name>
      <phone>49 30 450 666839</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Schneider</last_name>
      <phone>731 500 57401</phone>
      <email>nicole.schneider@uniklinik-ulm.de</email>
    </contact>
    <investigator>
      <last_name>Martin Wabitsch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Erika Van den Akker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2GW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaun Bolton</last_name>
      <phone>0044 121-371-6795</phone>
      <email>shaun.bolton@uhb.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Tarekegn Hiwot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>January 18, 2018</study_first_submitted>
  <study_first_submitted_qc>August 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2018</study_first_posted>
  <last_update_submitted>November 22, 2019</last_update_submitted>
  <last_update_submitted_qc>November 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>setmelanotide</keyword>
  <keyword>RM-493</keyword>
  <keyword>obesity</keyword>
  <keyword>leptin-melanocortin</keyword>
  <keyword>melanocortin 4 receptor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

